BCD-225 is an interleukin-15 superagonist, an original investigational product for human use being developed for the treatment of malignancies.
BCD-225 is a complex protein consisting of an active fragment of interleukin-15, which is bound to an active fragment of the soluble interleukin-15 receptor for higher efficacy and inserted in place of the variable fragments of the monoclonal antibodies (responsible for specific binding to the target) to improve the pharmacological properties.
A monoclonal antibody is a protein created by scientists in a laboratory, similar to the natural antibodies of the immune system, designed to bind to a specific target in the human body1.
Interleukin-15 is a molecule with a wide range of biological functions that is involved in the signaling pathways activating innate immune cells, which are also responsible for tumor cell destruction2. Many functions of interleukin-15 require its binding to the interleukin-15 receptor on the surface of immune cells. The monoclonal antibody fragments in the BCD-225 molecule allow it to attract immune cells mimicking natural interleukin-15.
The safety and anticancer activity of BCD-225 have been confirmed in non-clinical studies in animals. Investigational product BCD-225 has not been previously used in humans, so its efficacy and adverse effects in humans are currently unknown.
In the clinical study, BCD-225 is administered subcutaneously. The physician-investigator closely monitors the patient’s condition throughout their participation in the study and will take all necessary actions to manage adverse events if they occur. To reduce the risk of adverse reactions, all patients are given antiallergic and antipyretic drugs before the administration of BCD-225.
- Breedveld FC. Therapeutic monoclonal antibodies. The Lancet. 2000;355(9205):735-40.
- Anjali Mishra, Laura Sullivan, Michael A. Caligiuri; Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer. Clin Cancer Res 15 April 2014; 20 (8): 2044–2050.
This section of the website contains information about an unauthorized investigational product for human use.